Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo

View ORCID ProfileMarina Antillon, Ching-I Huang, View ORCID ProfileRonald E. Crump, Paul E. Brown, View ORCID ProfileRian Snijders, Erick Mwamba Miaka, View ORCID ProfileMatt J. Keeling, View ORCID ProfileKat S. Rock, View ORCID ProfileFabrizio Tediosi
doi: https://doi.org/10.1101/2020.08.25.20181982
Marina Antillon
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marina Antillon
Ching-I Huang
3Zeeman Institute, University of Warwick, Coventry, UK
4Mathematics Institute, University of Warwick, Coventry, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald E. Crump
3Zeeman Institute, University of Warwick, Coventry, UK
4Mathematics Institute, University of Warwick, Coventry, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ronald E. Crump
Paul E. Brown
3Zeeman Institute, University of Warwick, Coventry, UK
4Mathematics Institute, University of Warwick, Coventry, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rian Snijders
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
5Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rian Snijders
Erick Mwamba Miaka
6Programme National de Lutte contre la Trypanosomie Humaine Africaine, Kinshasa, Democratic Republic of Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matt J. Keeling
3Zeeman Institute, University of Warwick, Coventry, UK
4Mathematics Institute, University of Warwick, Coventry, UK
7School of Life Sciences, University of Warwick, Coventry, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matt J. Keeling
Kat S. Rock
3Zeeman Institute, University of Warwick, Coventry, UK
4Mathematics Institute, University of Warwick, Coventry, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kat S. Rock
Fabrizio Tediosi
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabrizio Tediosi
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission (EOT) by 2030, but the disease persists in several low-income countries. We coupled transmission and health outcomes models to examine the cost-effectiveness of four gHAT elimination strategies in in five settings – spanning low- to high-risk – of the Democratic Republic of Congo. Alongside passive screening (PS) in fixed health facilities, the strategies included active screening (AS) at average or intensified coverage levels, alone or with vector control (VC) with a scale-back algorithm when no cases were reported for three consecutive years. In high or moderate-risk settings, costs of gHAT strategies are primarily driven by AS and, if used, VC. Due to the cessation of AS and VC, most investments (75-80%) will be made by 2030 and VC might be cost-saving while ensuring EOT. In low-risk settings, costs are driven by PS, and minimum-cost strategies consisting of AS and PS lead to EOT by 2030 with high probability.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Bill and Melinda Gates Foundation (www.gatesfoundation.org) through the Human African Trypanosomiasis Modelling and Economic Predictions for Policy (HAT MEPP) project [OPP1177824] (MA, CH, REC, PB, MJK, KSR, and FT), through the NTD Modelling Consortium [OPP1184344, OPP1156227, and OPP1186851] (KSR and MJK), and through the TRYP-ELIM-BANDUNDU project [OPP1155293] (EMM and RS) and the Directorate-general Development Cooperation and Humanitarian Aid (EMM). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Because no personal data were used (only projections and data from the literature) the submitted work is exempt from ethics oversight.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Format for a new journal.

Data Availability

Full model (including the fitting code) and documentation are available through OpenScienceFramework (OSF).

https://osf.io/xbwte/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo
Marina Antillon, Ching-I Huang, Ronald E. Crump, Paul E. Brown, Rian Snijders, Erick Mwamba Miaka, Matt J. Keeling, Kat S. Rock, Fabrizio Tediosi
medRxiv 2020.08.25.20181982; doi: https://doi.org/10.1101/2020.08.25.20181982
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo
Marina Antillon, Ching-I Huang, Ronald E. Crump, Paul E. Brown, Rian Snijders, Erick Mwamba Miaka, Matt J. Keeling, Kat S. Rock, Fabrizio Tediosi
medRxiv 2020.08.25.20181982; doi: https://doi.org/10.1101/2020.08.25.20181982

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)